Cytophage Technologies Ltd. logo

Cytophage Technologies Ltd. (CYTO)

Delisted
25 May 2026
NEO-L NEO-L
CA$
0. 00
-0.02
-83.3333%
CA$
- Market Cap
- P/E Ratio
- Div Yield
67,835 Volume
- Eps
CA$ 0.03
Previous Close
Day Range
0 0.01
Year Range
0 0.31
Want to track CYTO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

CYTO Chart

Cytophage Technologies Ltd. (CYTO) FAQ

What does "Delisted" mean?

Cytophage Technologies Ltd. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

No stock splits were recorded prior to delisting.

What was the last known trading price?

The stock last traded at CA$0.00 on May 25, 2026 before being delisted.

Cytophage Technologies Ltd. Profile

Biotechnology Industry
Healthcare Sector
Dr. Steven Theriault B.Sc., M.Sc., Ph.D. CEO
NEO-L Exchange
- ISIN
Canada Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Cytophage Technologies Ltd. is an innovative biotechnology company that focuses on the research, development, and commercialization of bacteriophage therapies. These therapies are designed to combat bacterial infections that impact human health, animal health, and food security. Based in Winnipeg, Canada, Cytophage Technologies is at the forefront of using bacteriophages, viruses that infect and destroy bacteria, as a means to address some of the most pressing health concerns today. Their work includes developing products aimed at improving poultry health, ensuring food safety, treating bovine mastitis, and offering solutions for livestock producers to manage bacterial infections more effectively.

Products and Services

  • AviPhage:

    Cytophage's AviPhage line of products is targeted towards the poultry industry. These products are designed to prevent and treat bacterial infections in poultry, thereby improving the overall health of birds and enhancing poultry production efficiency.

  • PhageFend:

    The PhageFend range focuses on food safety, offering solutions to combat bacterial contaminants in the food supply chain. By leveraging bacteriophage technologies, PhageFend aims to reduce the presence of harmful bacteria in food products, ensuring safer consumption for end-users.

  • BoviPhage:

    Addressing the issue of bovine mastitis, an infection of the mammary glands in dairy cows, BoviPhage products offer a bacteriophage-based therapy. This application ensures dairy herds remain healthy and productive, ultimately benefiting dairy farmers by reducing the impact of this prevalent condition.

  • FarmPhage:

    FarmPhage products offer a water-soluble solution for livestock producers. This innovative approach allows for the easy administration of bacteriophage therapies to livestock through their drinking water, aiding in the prevention and treatment of bacterial infections across a range of animal species.

Contact Information

Address: 26 Henlow Bay
Phone: -